Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00048555
Status:
COMPLETED
Last Update Posted:
2013-09-16
First Post:
2002-11-01
Brief Title:
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkins Lymphoma
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
A Phase III Trial of IDEC-114 Anti-CD80 Monoclonal Antibody in Combination With Rituxan for Patients With Relapsed or Refractory Follicular Lymphoma
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine what side effects and what clinical effect if any the administration of this investigational product IDEC-114 in combination with Rituxan Rituxan as a single agent is approved by the United States Food and Drug Administration FDA to treat patients with relapsed or refractory follicular NHL has in this patient population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None